Experimental autoimmune encephalomyelitis (EAE) is a demyelinating disease of the central nervous system (CNS) that shares clinical and pathophysiological feature with multiple sclerosis (MS) and is commonly used as an animal model for the human disease. Upon active immunization, different myelin proteins and other neuronal antigens are known to induce EAE in susceptible mouse strains. However, there are rodent strains reputed to be resistant to actively-induced EAE and the correct combination of animal strains and their respective autoantigen is absolutely critical as some antigens are encephalitogenic in one animal strain, but not in another. Here we describe actively-induced EAE in C3H/HeJ mice with different myelin peptides. Whereas no clinical signs could be found by immunization with myelin oligodendrocyte glycoprotein 35-55, significant weight loss as well as rapidly occurring severe ascending paralysis was found in animals immunized with proteolipid protein 190-209 (PLP(190-209)). Histologically, this form of EAE was characterized by predominant involvement of the spinal cord. As PLP is one of the major lipid antigens putatively involved in the pathogenesis of MS, this model may be useful for further studies of the disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jim.2010.12.018 | DOI Listing |
Expert Rev Vaccines
January 2025
Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Introduction: Pertussis poses a significant threat to infants under six months due to their immature immune systems, limited maternal antibody protection, and constraints in the vaccination schedule. Despite vaccination efforts, this group remains highly susceptible to severe complications. Addressing these challenges is crucial for improving the health outcomes of infants in China.
View Article and Find Full Text PDFJAMA Intern Med
January 2025
Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
Importance: SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) contribute to many hospitalizations and deaths each year. Understanding relative disease severity can help to inform vaccination guidance.
Objective: To compare disease severity of COVID-19, influenza, and RSV among US veterans.
J Virol
January 2025
MRC Translational Immune Discovery Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Unlabelled: Current influenza vaccination approaches protect against specific viral strains, but do not consistently induce broad and long-lasting protection to the diversity of circulating influenza viruses. Single-cycle viruses delivered to the respiratory tract may offer a promising solution as they safely express a diverse array of viral antigens by undergoing just one round of cell infection in their host and stimulate broadly protective resident memory T-cell responses in the lung. We have previously developed a vaccine candidate called S-FLU, which is limited to a single cycle of infection by inactivation of the hemagglutinin signal sequence and induces a broadly cross-reactive T-cell response and antibodies to neuraminidase, but fails to induce neutralizing antibodies to hemagglutinin after intranasal administration.
View Article and Find Full Text PDFJ Med Virol
February 2025
Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, P. R. China.
Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can be induced through either infection with the virus or vaccination, providing protection against reinfection or reducing the risk of severe clinical outcomes. In this study, we recruited 172 volunteers who received different vaccination regimens, including 124 individuals who had recovered from breakthrough infections caused by the Omicron variant (27 with 2 doses, 49 with 3 doses, and 48 with 4 doses) and 48 healthy donors who did not experience breakthrough infections (all of whom received a fourth dose during the infection wave). We measured neutralizing antibody levels against Omicron BA.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Crucell Integration, Janssen Research and Development, Beerse, Belgium.
We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 10 viral particles [vp]) in healthy adolescents aged 12-17 years.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!